0 Items
Select Page

Saint Louis Encephalitis Virus

Saint Louis Encephalitis virus (SLEV) is an emerging virus that causes encephalitis in humans. St Louis encephalitis (SLE) is an arthropod borne-disease transmitted by mosquitoes of the Culex species. In humans, SLEV infection is often asymptomatic and goes undiagnosed but, in some cases, neurological complications develop leading to coma and sometimes death.

The Native Antigen Company supply highly purified recombinant SLEV proteins to support SLEV research and assay development.

Saint Louis Encephalitis Virus Background

Saint Louis encephalitis virus (SLEV) is an enveloped, single-stranded, positive-sense RNA virus that belongs to the genus Flavivirus. It is a member of the Japanese encephalitis sero-complex of the family Flaviviridae, which also includes Japanese encephalitis virus, West Nile virus and Murray Valley encephalitis virus.

In nature, St. Louis Encephalitis virus is maintained in a cycle between mosquitoes of the Culex species and wild birds, which do not develop disease and act as amplifying hosts. Mosquito vectors can also transmit SLEV to humans and domestic animals, which act as dead-end hosts for the virus. SLEV is geographically widespread from Canada to South America, with most reported cases of human SLEV infection occurring in North America (Diaz, A).

In humans, SLEV infection causes the neuro-invasive disease known as St. Louis Encephalitis (SLE) but most cases are clinically asymptomatic and remain undiagnosed. A small percentage of patients present with symptoms of disease including headache, fever, nausea and general malaise. Some individuals recover but in rare cases, patients may further develop neurological complications including aseptic meningitis, encephalitis and coma, which can lead to death. Severity of disease and mortality due to SLEV infection is reported to increase with age, with approximately 90% of geriatric patients developing encephalitis (CDC).  

Currently, no antiviral therapy or licensed vaccine is available for the treatment and prevention of SLEV infection. Owing to the difficulty of isolating SLE from clinical samples, diagnosis of SLEV infection is commonly performed using serological methods to detect SLEV specific antibodies in serum and cerebrospinal fluid.

References

Diaz, A. et. al. (2018). Reemergence of St. Louis Encephalitis Virus in the Americas. Emerging Infectious Diseases24(12), 2150-2157. 

Centers of Disease Control and Prevention: St Louis Encephalitis.

Saint Louis Encephalitis Virus Antigens

The Native Antigen Company have developed recombinant Saint Louis Encephalitis virus proteins in our mammalian cell expression system. These antigens are suitable for use in assay development, vaccine research and as antigens for the preparation of specific antibodies.

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

Why We Need Antigen and Antibody Tests for COVID-19

RT-PCR is the workhorse of viral diagnosis and has been invaluable in COVID-19 case confirmation and isolation guidance. However, while fast and sensitive, PCR suffers from some inherent drawbacks that limit it to diagnosis during the acute phase of infection. To...

Gonorrhea: What’s Currently in the Clinical Pipeline?

This article was written by our friends at Infectious Diseases Hub, a free-to-access website that aims to deliver up-to-date, essential research and information on all aspects of microbiology, virology, mycology and parasitology – from bench to bedside....

Novel Coronavirus Antigens Now Available

The Native Antigen Company is now offering recombinant S1 and S2 glycoproteins for SARS-CoV-2 (Covid-19) in response to urgent demand. These reagents are suitable for use in basic research and the development of diagnostics and vaccines.These antigens have been...

The Why and How of Protein Conjugation

In this blog, Lead Assay Development Scientist, Toni Ertl discusses the basics of protein conjugation and introduces our new range of conjugation kits for the labelling of antigens and antibodies.Detecting Proteins If you’re trying to detect or measure the presence...

Going Viral: Why We Need New Diagnostics For a Safe and Effective Dengue Vaccine

This article is taken from European Biopharmaceutical Review January 2020, pages 44-46. © Samedan Ltd.The Dengue VirusDengue is the world’s most prevalent and consequential arboviral disease. Current estimates indicate that as many as 390 million dengue infections...

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

12 + 12 =

Live Customer Feedback

Join our mailing list

* indicates required